SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Western Digital Corp. engages in the development, manufacture, marketing, and sale of data storage devices and solutions. It operates through the Hard Disk Drives (HDD) segment. The company was founded by Alvin B. Phillips in 1970 and is headquartered in San Jose, CA.

Western Digital Corp.

Western Digitals strong earnings and upbeat guidance are drawing attention, but shares sold off anyway. Traders are debating whether the drop reflects elevated expectations, rising spending and cyclical peak concerns, or an overreaction to results that point to robust AI-related storage demand.

The Charles Schwab Corp. is a savings and loan holding company, which engages in the provision of wealth management, securities brokerage, banking, asset management, custody, and financial advisory services. It operates through the Investor Services and Advisor Services segments. The Investor Services segment includes retail brokerage, investment advisory, and banking and trust services to individual investors, retirement plan and business services, as well as other corporate brokerage services, to businesses and employees. The Advisor Services segment provides custodial, trading, banking and trust, and support services to independent registered investment advisors, independent retirement advisors, and recordkeepers. The company was founded by Charles Robert Schwab in 1986 and is headquartered in Westlake, TX.

Charles Schwab Corp.

Reports of widespread Schwab and thinkorswim outages, including login, quote, and order-entry problems, dominate the discussion. Traders are frustrated over missed or disrupted trades and threaten to move brokers, while some report that service has been restored.

Nokia Oyj engages in the provision of network infrastructure, technology, and software services. It operates through the following segments: Mobile Networks, Network Infrastructure, Cloud and Network Services, and Nokia Technologies. The Mobile Networks segment offers technologies for Radio Access Networks (RAN) as well as Microwave Radio Links (MWR) for transport networks. The Network Infrastructure serves communication service providers, enterprises, webscales and public sector customers. The Cloud and Network Services segment builds around software and the cloud and is focused on driving leadership in cloud-native software and as-a-service delivery models, as demand for critical networks accelerates; and with strong market positions in communications software, private wireless networks, and cognitive (or intelligent) services. The Nokia Technologies segment, building on decades of innovation and R&D leadership in technologies used in virtually all mobile devices used today, is expanding the Nokia patent licensing business, reintroducing the Nokia brand to smartphones through brand licensing, and establishing a technology licensing business. The company was founded by Fredrik Idestam in 1865 and is headquartered in Espoo, Finland.

Nokia Corp - ADR

Nokia Corp

Nokia shares sold off sharply after its quarterly report despite beating expectations, as traders focused on weaker cash-flow guidance, higher restructuring costs, and managements warning that supply-chain cost increases may persist. Bulls call the reaction an overreaction and point to strong AI and cloud demand, while bears question whether that growth can translate into cash and margins.

Direxion Shares ETF Trust - Direxion Daily Semiconductor Bull 3X ETF

Direxion Daily Semiconductor Bull 3X Shares

SOXL is drawing attention after a sharp drop amplified a semiconductor-sector selloff, with traders citing LAM Researchs warning about component supply constraints and worries over AI-chip spending and valuations. The community is split between viewing the decline as an oversold buying opportunity and expecting further losses amid chip weakness and the funds 3x leverage.

Precigen, Inc. is a biotechnology company, which engages in the research and development of synthetic biology technologies. It operates through the Biopharmaceuticals and Exemplar segments. The company was founded by Thomas David Reed in 1998 and is headquartered in Germantown, MD.

Precigen Inc

Precigens strong quarterly results and rapid PAPZIMEOS launch are the main focus, with traders highlighting growing sales and improving profitability. Bullish discussion also points to European and PRGN-2009 milestones and possible short covering, while others flag volatility and potential competition from INOVIOs pending RRP treatment.

Walmart, Inc. engages in the retail and wholesale business. The company offers an assortment of merchandise and services at everyday low prices. It operates through the following segments: Walmart U.S., Walmart International, and Sam's Club U.S. The Walmart U.S. segment operates as a mass merchandiser of consumer products, operating under the Walmart and Walmart Neighborhood Market brands, including walmart.com. The Walmart International segment includes operations of wholly-owned subsidiaries in Canada, Chile, China, and Africa, and majority-owned subsidiaries in India, as well as Mexico and Central America. The Sam's Club U.S. segment manages membership-only warehouse clubs and operates samsclub.com. The company was founded by Samuel Moore Walton and James Lawrence Walton on July 2, 1962 and is headquartered in Bentonville, AR.

Walmart Inc

Walmarts sharp rally through the $120 area and heavy call positioning are driving attention, with traders watching for further gains ahead of the November earnings report. Bulls see momentum continuing, while bears argue the stock is overextended and vulnerable to a pullback.

SK hynix, Inc. engages in the design, manufacture, and sale of semiconductor products. Its products include dynamic random access memory, not-AND flash memory, and multi-chip package. The company was founded on October 15, 1949 and is headquartered in Icheon, South Korea.

SK Hynix Inc - ADR

SK Hynix is drawing attention amid a sharp selloff in memory and AI-chip stocks alongside weakness in South Koreas market; traders point to foreign-investor selling and concerns about AI demand, memory-cycle normalization and Chinese competition. Bulls call the drop overdone given HBM demand and the companys earnings potential, while bears warn that selling pressure may persist.

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

AbCellera Biologics Inc

Attention centers on AbCelleras ABCL635 clinical program for menopausal hot flashes, with traders focused on Phase 1/2 conference data and whether it adds evidence on durability, safety, and patient-reported outcomes beyond the positive Phase 2 topline. Many are bullish on the program, while others question whether the presentation offers meaningfully new information and point to volatility around the catalyst.

Forgent Power Solutions, Inc. is a holding company, which engages in the design and manufacture of electrical distribution equipment used in data centers, power grid, and energy-intensive industrial facilities. It also offers powertrain solutions and standard and custom products. The company was founded on July 21, 2025 and is headquartered in Dayton, MN.

Forgent Power Solutions Inc. - Ordinary Shares - Class A

Forgent Power Solutions Inc.

Forgent shares sold off sharply after CFO Ryan Fiedlers departure was announced, prompting debate over whether the transition is an overreaction or a sign of undisclosed financial problems. The company says the departure is unrelated to disagreements or its financial condition, and preliminary Q1 revenue and adjusted EBITDA are expected to exceed guidance; some traders view the update as reassurance and are buying the dip.

Bloom Energy Corp. engages in the manufacture and installation of a solid oxide fuel-cell based power generation platform. Its product, Bloom Energy Server, converts standard low-pressure natural gas or biogas into electricity through an electrochemical process without combustion. The company was founded by K. R. Sridhar, John Finn, Jim McElroy, Matthias Gottmann, and Dien Nguyen on January 18, 2001, and is headquartered in San Jose, CA.

Bloom Energy Corp - Ordinary Shares - Class A

Bloom Energys strong Q3 results and raised full-year outlook were met with a sharp selloff, prompting debate over whether heavy capital spending and negative cash flow, high expectations, and weakness in AI-linked stocks outweighed the growth story. Bulls view the drop as an overreaction and point to continued demand for data-center power, while skeptics question the valuation and cash generation.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Why Did KOD, RGEN, BIIB Stocks Rise To 52-Week Highs?

Equity

Shares of Kodiak Sciences, Repligen, and Biogen surged to annual highs amid positive company catalysts.

Merck's Remigromig Meets Main Goal in Diabetic Macular Edema Study

MRK's remigromig meets the primary goal in a DME study, showing non-inferiority to ranibizumab while further safety analyses continue.

AMGN's Dazodalibep Meets Goal in Systemic Sjogren's Disease Study

Amgen's dazodalibep meets its primary goal in a Phase III study, showing sustained improvement in systemic Sjogren's disease activity through week 48.

Alkermes Posts Positive Data From Phase I ADHD Study on ALKS 7290

ALKS posts positive Phase I data for ALKS 7290, showing meaningful improvements in ADHD symptoms across dose levels in healthy volunteers and adults.

JNJ's Caplyta Shows Benefit in Bipolar 1 Related Mania Study

J&J's Caplyta shows rapid and significant improvement in bipolar mania symptoms in a pivotal phase III study.

NVS Gets Positive CHMP Opinion for Cosentyx for Another Indication 

NVS' Cosentyx wins a positive EU opinion for PMR, backed by late-stage data, potentially expanding its use beyond existing inflammatory conditions.

Merck Gets CHMP Backing for Keytruda-Padcev Combo in Bladder Cancer

MRK's Keytruda plus Padcev combo gets CHMP backing as perioperative treatment for eligible patients with resectable muscle-invasive bladder cancer.

CHMP Backs CORT's Lifyorli Combo in Platinum-Resistant Ovarian Cancer

Corcept's Lifyorli plus nab-paclitaxel wins a positive CHMP opinion for platinum-resistant ovarian cancer, with an EC decision expected in Q4 2026.

PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins

Puma Biotechnology starts the ALISCA-Lung2 phase II study evaluating alisertib in combination with paclitaxel in patients with advanced small cell lung cancer.

RHHBY's Lunsumio Combo Meets Goal in 2L Follicular Lymphoma Study

Roche's Lunsumio-Revlimid combo meets its study goal in second-line or later follicular lymphoma, improving PFS versus rituximab plus Revlimid.

Repligen Corp. is a global life sciences company, which engages in providing bioprocessing technologies and solutions used in the process of manufacturing biological drugs. It operates through the North America. Europe, and Asia Pacific Region or Other geographical segments. The company was founded by Alexander G. Rich and Paul R. Schimmel in May 1981 and is headquartered in Waltham, MA.

Repligen Corp.

Neutral Sentiment

<ul class="summary-bullets"><li><a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> stock surged more than 177% at close after it said that its experimental drugs, Zenkuda and KSI-501, had met the primary endpoints in its Phase 3 Daybreak trial.</li><li>RGEN stock gained more than 2% at close, extending gains amid positive investor sentiment following its strong second-quarter 2026 earnings beat, increased full-year financial guidance, and expansion into cell therapy.</li><li>BIIB stock gained about 0.5% at close on Monday amid a buy-in following its strong second-quarter 2026 earnings, recent strategic acquisitions, and positive product pipeline updates.&nbsp;</li></ul>Shares of pharmaceutical companies Kodiak Sciences Inc. (<a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a>), Repligen Corp. (RGEN) and Biogen Inc. (BIIB) surged to fresh 52-week highs on Monday amid positive trial results and strong earnings reports.&nbsp;<a href="https://stocktwits.com/symbol/KOD">KOD stock</a> surged more than 177% at close after it said that its experimental drugs, Zenkuda and KSI-501, had met the primary endpoints in its Phase 3 Daybreak trial.<a href="https://stocktwits.com/symbol/RGEN">RGEN stock</a> gained more than 2% at close, extending gains amid positive investor sentiment following its strong second-quarter 2026 earnings beat, increased full-year financial guidance, and expansion into cell therapy.<a href="https://stocktwits.com/symbol/BIIB">BIIB stock</a> gained about 0.5% at close on Monday amid a buy-in following its strong second-quarter 2026 earnings, recent strategic acquisitions, and positive product pipeline updates.&nbsp;<h2 class="st-heading-2">Kodiak Sciences Makes It To September’s Top Five Biotech Gainers</h2><a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> stock jumped to a 52-week high of $95.77 on Monday, its steepest climb on record, after the company scored a major drug win.&nbsp;Kodiak&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/kod-stock-september-top-5-biotech-gainers-eye-drug-shkreli-still-sucks/cZMmZ2VRBXj">said</a> Monday that its two experimental therapies, Zenkuda and KSI-501, met the primary endpoints in the Phase 3 Daybreak trial, with both delivering vision improvements that were non-inferior to those seen with 2-mg aflibercept, the active ingredient in Regeneron’s original Eylea.&nbsp;The company reported no cases of intraocular inflammation in the Zenkuda arm and plans to seek regulatory approval in the fourth quarter, supported by positive data from five Phase 3 studies spanning three eye diseases.&nbsp;KSI-501, also known as Tabirafusp-ted, uses a different mechanism, and Kodiak plans additional analyses to determine whether certain wet AMD patients could benefit from its IL-6-targeting component. A separate Phase 3 study is evaluating KSI-501 in diabetic macular edema.On Stocktwits, retail sentiment around <a class="mention" data-mention="$KOD" data-symbol-id="KOD" href="https://stocktwits.com/symbol/KOD" target="_blank">KOD</a> stock was ‘extremely bullish’ at the time of writing. The company's shares have rallied more than 245% in 2026.&nbsp;<h2 class="st-heading-2">Repligen Extends Gains From Strong Quarter 2026&nbsp;</h2>RGEN stock climbed to a 52-week high of $198.87 on Monday, putting it on track for a sixth straight month of gains amid strong earnings, higher full-year guidance, and a major expansion into cell therapy.The company reported Q2 revenue of $204.1 million, up about 12% year over year, while adjusted earnings per share of $0.54 exceeded analyst expectations. Management subsequently raised its 2026 organic revenue-growth outlook to 10.5%-13.5% and increased adjusted EPS guidance to $2.03-$2.09.&nbsp;Repligen also recently agreed to acquire BioLife Solutions for approximately $1.5 billion, expanding its portfolio into cell-therapy biopreservation and strengthening its position in the growing cell and gene therapy market. The transaction is expected to broaden Repligen’s addressable market and add complementary products and capabilities.&nbsp;On Stocktwits, retail sentiment around RGEN stock was ‘bullish’ at the time of writing. The company's shares are up more than 18% this year.&nbsp;<h2 class="st-heading-2">Biogen Rises On The Back Of Strong Earnings, Positive Product Pipeline Updates</h2>BIIB stock rose to an annual high of $230.49 on Monday, putting it on track for a second consecutive month of gains as investors responded to strong second-quarter 2026 results, accelerating growth across its newer products and a series of pipeline and strategic developments.&nbsp;The company’s growth portfolio generated $1.06 billion in Q2 revenue, up 24% year-over-year, driven by continued launches and sales momentum for Skyclarys, Qalsody, Zurzuvae and Leqembi.Biogen also reported several pipeline catalysts. Leqembi received approval in Japan for a more convenient pen-based, at-home administration and a new formulation, Leqembi Iqlik.&nbsp;The company agreed to acquire RayThera for about $1 billion, strengthening its immunology portfolio, while Salanersen received FDA Breakthrough Therapy designation for spinal muscular atrophy.&nbsp;Biogen also highlighted encouraging clinical data for Zorevunersen in Dravet syndrome.On Stocktwits, retail sentiment around BIIB stock was ‘neutral’ at the time of writing. The company's shares have gained more than 28% in 2026.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

In this photo illustration, the Kodiak Sciences logo is seen displayed on a smartphone screen. (Photo Illustration by Thomas Fuller/SOPA Images/LightRocket via Getty Images)

Biogen Inc

Kodiak Sciences Inc

Very bullish

Cautiously bullish

Cautiously bearish

Very bearish

Stocktwits sentiment on $SPY just hit its lowest level of the year. How are you feeling about the market right now?

Stocktwits

 just hit its lowest level of the year. How are you feeling about the market right now?

Feed

News

Sentiment

Earnings

Fundamentals

Info

RGEN Repligen Corp.

Fundamentals

Latest RGEN News